CSII - CSII STOCK NEWS

Cardiovascular Systems, Inc. (CSII) reported third-quarter fiscal 2022 revenues of $56.2 million, reflecting an 11.1% decline year-over-year and a 4.9% sequential decrease. The company has narrowed its revenue guidance for the fiscal year to $235 million to $240 million. Despite challenges from COVID-19, the CEO noted encouraging sales momentum and anticipated gradual improvement in procedure volumes. The company is advancing its product pipeline, including a partnership with Innova Vascular for thrombectomy devices and successful trials for its drug-coated balloon and ventricular assist device.

Cardiovascular Systems, Inc. (CSII) will release its operating results for the quarter ending March 31, 2022, on May 4, 2022, before market opening. A conference call to discuss these results is scheduled for 8:00 a.m. CT (9:00 a.m. ET) on the same day. The company specializes in medical devices aimed at treating vascular and coronary diseases, particularly through its advanced orbital atherectomy system, which targets calcified and fibrotic plaque.

Cardiovascular Systems, Inc. (CSII) announced plans to present and host investor meetings at two significant healthcare conferences. The 21st Annual Needham Virtual Healthcare Conference will take place on April 12, 2022, at 10:15 a.m. ET, followed by the BofA Securities 2022 Healthcare Conference on May 10, 2022, at 4:00 p.m. ET. Investors can access live webcasts and replays on the company’s investor relations webpage. CSII focuses on innovative treatment solutions for vascular diseases, particularly through its orbital atherectomy system.

Cardiovascular Systems, Inc. (CSII) has announced the first in-human experience with its Propel™ percutaneous ventricular assist device (pVAD) during high-risk percutaneous coronary interventions (HR-PCI). Treated by Dr. David E. Kandzari in Tbilisi, Georgia, Propel demonstrated effective hemodynamic support, leading to successful revascularization. The device’s smaller profile may reduce clinical complications and expand its use in patients with challenging anatomies. The success of these initial cases boosts CSII's confidence in Propel's future and informs U.S. feasibility studies.

Cardiovascular Systems, Inc. (CSII) has commenced enrollment for a first-in-human trial of its peripheral everolimus drug-coated balloon (DCB) developed by Chansu Vascular Technologies (CVT). The trial aims to enroll 75 patients across Germany and France to support FDA submission. The first patient, treated for a femoral artery lesion, demonstrates the potential of everolimus DCBs to enhance treatment outcomes for peripheral artery disease. CSII has also agreed to provide milestone-based financing to CVT and has the option to acquire CVT upon the completion of specific milestones.

Cardiovascular Systems, Inc. (CSII) has appointed Dr. Jeffery W. Chambers as Chief Medical Officer, aiming to enhance its product pipeline in interventional cardiology. Dr. Chambers brings extensive clinical research experience, having previously led pivotal trials for the company's products. Under his leadership, CSII plans to focus on developing innovative solutions, including everolimus drug-coated balloons and thrombectomy devices. This leadership change is expected to bolster the company's strategy to address coronary and peripheral artery diseases effectively.

Cardiovascular Systems, Inc. (CSII) has partnered with Innova Vascular, Inc. to develop and commercialize a new line of thrombectomy devices aimed at treating peripheral vascular diseases, including deep vein thrombosis and pulmonary embolism. This partnership aligns with CSII’s strategy to enhance its product portfolio and address the growing interventional procedure market, projected to be worth over $18 billion in the coming years. CSII plans to begin commercialization pending regulatory clearance in fiscal 2023.

Cardiovascular Systems, Inc. (CSII) reported Q2 fiscal 2022 revenues of $59.1 million, a 7.8% decline year-over-year, primarily due to procedural volume reductions from hospital capacity issues related to Covid-19. The company anticipates fiscal year revenues between $235 million and $245 million, a downward revision reflecting ongoing challenges. Notably, CSII announced FDA PMA approval for the Scoreflex® NC scoring balloon and continued progress in developing intravascular lithotripsy technology.

Cardiovascular Systems, Inc. (CSII), a medical device company based in St. Paul, Minnesota, announced its participation in the SVB Leerink 2022 Global Healthcare Conference on February 18, 2022, at 12:00 p.m. ET. The company specializes in innovative interventional treatment systems for patients with peripheral and coronary artery disease. A webcast of the presentation will be available here.